Metastatic Breast Cancer
News
Cost paramount when choosing metastatic breast cancer treatment
“Our analysis provides quantifiable evidence to help providers choose lower priced, but equally effective sequences of drugs.”
News
FDA OKs selpercatinib for adults with RET-fusion+ solid tumors
In 2020, selpercatinib received accelerated approval for lung and thyroid RET-positive tumors.
Conference Coverage
High BMI linked to better survival for cancer patients treated with ICI, but for men only
The reasons behind the findings and implications for treatment are unknown, as is whether it applies to patients with specific cancers.
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Conference Coverage
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.
News
Tumor-bed radiotherapy boost reduces DCIS recurrence risk
Regardless of the whole breast irradiation fractionation schedule, a 16 Gy tumor-bed boost halved the risk of DCIS recurrence at 5 years.
News
Getting cancer research on track again may require a ‘behemoth’ effort
Cancer Moonshot aims to cut cancer-related deaths in half, but funding and pandemic challenges may hinder progress.
News
FDA approves trastuzumab-deruxtecan for HER2-low breast cancer
Sixty percent of patients previously classified as having HER2-negative subtype are now considered HER2 low.
News
Node-negative triple-negative breast cancer prognosis lies within stromal lymphocytes
Every 10% increase in stromal tumor-infiltrating lymphocytes was associated with a 19% reduction in the risk of death.
News
Life and death decisions: What keeps oncologists up at night
“It’s part of the discomfort you live with as a patient and oncologist, and when I leave the clinic, that’s one thing that follows me home.”